Dupilumab for hair regrowth in children with alopecia areata
Official title: Dupilumab in the Treatment of Pediatric Alopecia Areata
Funded at Icahn School of Medicine at Mount Sinai · NIH-11322610 · Data updated 2026-11-12
This project gives dupilumab to children and teens with widespread alopecia areata, especially those with allergies or high IgE, to help their hair grow back.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,309,584 |
| NIH project number | 5U01AI179629-03 |
| Project ID | NIH-11322610 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents with extensive (≥50%) scalp hair loss from alopecia areata, particularly those with atopic dermatitis, allergies, or high blood IgE levels, would be ideal candidates.
✕Less likely to help
Patients without an atopic background or low IgE, those with very limited scalp involvement, or individuals who cannot receive dupilumab may be less likely to benefit.
What this research studies
You or your child would receive regular dupilumab injections and be followed over time to track hair regrowth and side effects. The study focuses on pediatric patients with extensive scalp hair loss and often an atopic history like eczema or high IgE. Doctors will take photos, clinical hair counts, and small scalp samples to study immune signals linked to response. The team is building on adult results that showed hair regrowth with dupilumab to see if similar benefit occurs in younger patients.
Why it matters
Potential benefit: If successful, this could help children with extensive alopecia areata regrow scalp hair and provide a safer targeted option for long-term treatment.
How similar studies have gone: A prior clinical trial in adults with alopecia areata reported significant hair regrowth and molecular changes with dupilumab, so this pediatric effort builds on promising adult results.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Guttman, Emma — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guttman, Emma
Related research
Other NIH-funded projects on the same topics.
-
Targeting the NKG2A immune pathway to treat alopecia areata
This project will try blocking the NKG2A immune signal to reduce the immune attack on hair follicles and help people with alopecia areata regrow hair.
-
How IL-27 affects hair loss in alopecia areata
Researchers are exploring whether the immune molecule IL-27 helps stop the immune attack that causes hair loss in people with alopecia areata.
-
Using hydrogels to treat hair loss in alopecia areata
This study is exploring a new gel treatment for people with alopecia areata, a condition that causes hair loss, to see if it can help stimulate hair regrowth in a safe and effective way.
-
Using dupilumab to treat hair loss in children with alopecia areata
This study is looking at how a medication called dupilumab can help kids with alopecia areata, a condition that causes hair loss, by encouraging hair regrowth and making sure the treatment is safe and effective for them.
-
Investigating the NKG2A pathway to treat hair loss in alopecia areata
This study is looking at alopecia areata, a condition that causes hair loss, and is exploring new ways to help by targeting certain immune cells; if you're dealing with this condition, you might have a chance to join trials testing these exciting new treatments.
-
Investigating the role of IL-27 in hair loss caused by autoimmune disease
This study is looking at how a substance called IL-27 affects the immune system in people with alopecia areata, a condition that causes hair loss, to find new ways to help treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.